Physician profile
John R Behm
NPI 1528012366
$5,421.39
in general payments reported to CMS, 2019-2025
39 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $889 · 2021: $1,274 · 2022: $858 · 2023: $488 · 2024: $603 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $930.23 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $606.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $569.39 | 2021-2025 | Ubrelvy, Vraylar |
| Lilly USA, LLC | $308.03 | 2019-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $258.87 | 2019-2023 | |
| Glaxosmithkline, LLC. | $251.57 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $234.89 | 2019-2020 | |
| Amarin Pharma, INC. | $221.96 | 2019-2022 | |
| Novo Nordisk INC | $219.31 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $187.12 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $170.17 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $153.00 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $139.29 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.41 | 2020-2022 | |
| Axsome Therapeutics, INC. | $93.84 | 2023-2025 | Auvelity, Sunosi |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Behm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.